Journal
JOURNAL OF THORACIC ONCOLOGY
Volume 4, Issue 11, Pages 1352-1356Publisher
LIPPINCOTT WILLIAMS & WILKINS
DOI: 10.1097/JTO.0b013e3181bbf1dc
Keywords
FDG-PET; Lung cancer screening; Standardized uptake value
Categories
Funding
- Italian Ministry of Health (Ricerca Finalizzata)
- Italian Association for Cancer Research (AIRC)
- European Institute of Oncology
Ask authors/readers for more resources
Background: Fluorodeoxyglucose-positron emission tomography (FDG-PET) has proven its value in the diagnosis of undetermined pulmonary lesions, lung cancer staging, and assessment of prognosis. Purpose of this study is to clarify whether standardized uptake value (SUV) can predict clinical outcome of computed tomography (CT) screening detected lung cancer. Methods: We tested the predictive value of FDG-PET using SUV on long-term Survival of 34 lung cancer patients, detected from 1035 heavy smokers >= 50 years monitored by annual low-dose CT for 5 years, with a median follow-up of 75 months from diagnosis. Findings: PET scan was performed in 34 (89%) of 38 lung cancer patients diagnosed during the 5 years of screening and was positive in 32 (94%). Complete resection was achieved in 30 cases (88%), 20 (59%) were pathologic stage I and 23 (68%) were adenocarcinoma. Median SUV was 5.0 overall, being significantly lower in stage 1 (2.5 vs. 10.1, p = 0.00 1) and in adenocarcinoma (2.5 vs. 13.0, p = 0.001). The 5-year survival of lung cancer patients was 100% for SUV levels <= 2.5, 60% for SUV more than 2.5 and less than 8, and only 20% for SUV >= 8 (p = 0.001). Conclusions: FDG-PET using SUV can predict long-term Survival of screening detected lung cancer, in a noninvasive manner. Metabolic assessment of biologic behavior might improve the clinical management of CT-detected lung cancer and reduce the risk of unnecessary treatments for indolent disease.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available